Valley Behavioral Services is now Risk Evaluation and Mitigation Strategy (REMS) certified to provide Spravato (esketamine) CIII, a nasal spray approved for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD). People who are currently struggling with major depressive disorder (MDD) may have TRD if they have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.
According to the National Institute of Mental Health, MDD is one of the most common mental health disorders in the United States. For many people, treatments such as therapy, medicine and lifestyle changes may help relieve symptoms. However, up to one-third of adults may have TRD and continue to experience symptoms such as persistent feelings of sadness, sleep disturbances, low energy and thoughts of death or suicide, despite trying multiple treatments.
Spravato was approved by the U.S. Food & Drug Administration on March 5, 2019 and is only available to patients at REMS-certified treatment centers in the United States.